The Conversation (0)
Aevi Genomic Medicine released the company’s financial results for the first quarter of 2017 and announced it will be moving forward with a Phase 2 clinical trial of AEVI-001.
Aevi Genomic Medicine (NASDAQ:GNMX) released the company’s financial results for the first quarter of 2017 and announced it will be moving forward with a Phase 2 clinical trial of AEVI-001.
As quoted in the press release:
“Following additional analysis of the SAGA trial, we remain positive about the genetic subset of patients identified that demonstrate a clear and statistically significant response to AEVI-001,” said Mike Cola, CEO of Aevi Genomic Medicine. “This discovery will allow us to move forward with the development of AEVI-001 in ADHD, and potentially other neurodevelopmental disorders in the future, including Autism Spectrum Disorder. We look forward to initiating the Phase 2 trial of AEVI-001 in patients with the identified genetic subset during the second half of 2017 and anticipate announcing top-line data in mid-2018.”
Click here to read the full press release.
Source: www.newswire.ca